Zacks Investment Research
19 Jun 2026, 19:20 UTC · 4h ago
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
19 Jun 2026, 19:20 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA informed uniQure that three-year data from the phase I/II study of AMT-130 could serve as the primary basis for a biologics license application seeking accelerated approval. — This represents a critical regulatory pivot toward a faster path to market for a gene therapy targeting Huntington's disease, significantly reducing clinical risk.
+0.80uniQure expects to file its biologics license application (BLA) in the third quarter of 2026. — Provides a concrete timeline for a potential commercial catalyst, allowing investors to model future revenue milestones.
+0.40The FDA requires alignment on a confirmatory study design, specifically considering a standard-of-care control group instead of a sham-controlled design, prior to the BLA submission. — While the FDA is working 'expeditiously,' the requirement for additional study alignment introduces a layer of execution risk and potential delay.
-0.20Continue reading
6 related stories
Search tags
Which stocks this story touches
The company achieved a major regulatory milestone with the FDA regarding a potential accelerated approval path for its Huntington's disease therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
5h ago
